MapLight Therapeutics, Inc.

Stage 4 · Declining · week 7

As of Oct 22, 2026, MapLight Therapeutics is in Stage 4, the downtrend phase, now in week 7 (since Sep 8, 2026). It closed at $8.25, below its 200-day average, which is falling.

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. More about the company

$8.25

+1.10% today

$458M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MPLT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-10-27 → 2026-10-22

S? 41w

S4 6w

2025-10-272026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S3 3w → S4 6w current

Total tracked: 51 weeks across 3 stage runs.

MPLT among Biotechnology573rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…573	MPLTMapLight Therapeutics, Inc.	Stage 4 · wk 7	—	−23.4%

vs 52W High

—

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 7

1w13w26w

Week 7, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-60.4%

200 DMA: $20.81 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.68x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-23.4%

-77.4%

-71.7%

YTD

-50.8%

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 7 · Vol 0.68x

2026-10-21S4

Wk 7 · Vol 0.55x

2026-10-20S4

Wk 7 · Vol 0.68x

2026-10-19S4

Wk 6 · Vol 0.53x

2026-10-16S4

Wk 6 · Vol 0.68x

2026-10-15S4

Wk 6 · Vol 1.24x

2026-10-14S4

Wk 6 · Vol 0.84x

2026-10-13S4

Wk 6 · Vol 0.55x

2026-10-12S4

Wk 5 · Vol 0.86x

2026-10-09S4

Wk 5 · Vol 0.80x

2026-10-08S4

Wk 5 · Vol 0.32x

2026-10-07S4

Wk 5 · Vol 0.35x

Moving averages & range

50 DMA

$10.91

200 DMA

$20.81

52W High

—

52W Low

—

5D Low

$7.70

Resistance levels (recent highs)

20d High

$10.46

60d High

$14.03

120d High

$39.80

250d High

—

Next resistance

+26.8%

to 20d High

ROE

-111.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.1

MapLight Therapeutics: quick answers

What stage is MapLight Therapeutics in?

As of Oct 22, 2026, MapLight Therapeutics (MPLT) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 8, 2026 and is in week 7. What the four stages mean

Is MapLight Therapeutics in an uptrend?

No. MapLight Therapeutics is in a Stage 4 downtrend. It trades 60.4% below its 200-day average, which is falling.

How has MapLight Therapeutics performed over the past year?

As of Oct 22, 2026, MapLight Therapeutics is down 50.8% so far in 2026.

Which sector and industry is MapLight Therapeutics in?

MapLight Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.